Previous studies have demonstrated the efficacy of histone deacetylase (HDAC) inhibitors for the treatment of various metabolic diseases, such as obesity, type 1 and type 2 diabetes mellitus, non-alcoholic fatty liver disease, and even chronic kidney disease. Here, HDAC9 is linked to metabolic disease.